Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Efstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, Paolo Milani, Evangelos Terpos, Marco Basset, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostolakou, Maria Roussou, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Dimitrios C. Ziogas, Elektra Papadopoulou, Constantinos Pamboucas, Meletios A. Dimopoulos, Giovanni Palladini

Blood (2018) 131 (14): 1568–1575.

https://doi.org/10.1182/blood-2017-12-819904

Published: 2018

Includes: Supplemental data

Journal Articles

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Basset, Francesca Russo, Stefano Perlini, Giampaolo Merlini

Blood (2018) 131 (5): 525–532.

https://doi.org/10.1182/blood-2017-04-780544

Published: 2018

Includes: Supplemental data

Journal Articles

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Giovanni Palladini, MDPhD, Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 4346.

https://doi.org/10.1182/blood.V130.Suppl_1.4346.4346

Published: 2017

Journal Articles

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Giovanni Palladini, MDPhD, Ute Hegenbart, Paolo Milani, MD, Marco Basset, MD, Christoph Kimmich, MD, Francesca Russo, MD, Tilman Bochtler, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Stefan Schönland, MD

Blood (2017) 130 (Supplement 1): 1759.

https://doi.org/10.1182/blood.V130.Suppl_1.1759.1759

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

Paolo Milani, Marco Basset, Francesca Russo, Andrea Foli, Giampaolo Merlini, Giovanni Palladini

Blood (2017) 130 (5): 625–631.

https://doi.org/10.1182/blood-2017-02-767467

Published: 2017

Includes: Supplemental data

Journal Articles

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Basset, Francesca Russo, Stefano Perlini, Giampaolo Merlini

Blood (2017) 129 (15): 2120–2123.

https://doi.org/10.1182/blood-2016-12-756528

Published: 2017

Includes: Supplemental data

Journal Articles

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Giovanni Palladini, MD PhD, Margherita Massa, Marco Basset, MD, Francesca Russo, MD, Paolo Milani, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 3261.

https://doi.org/10.1182/blood.V128.22.3261.3261

Published: 2016

Journal Articles

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Efstathios Kastritis, MD, Giampaolo Merlini, MD, Ioannis Papassotiriou, PhD, Paolo Milani, MD, Evangelos Terpos, Marco Basset, MD, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostoloakou, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Constantinos Pamboucas, Elektra Papadopoulou, Meletios A Dimopoulos, Giovanni Palladini, MD PhD

Blood (2016) 128 (22): 648.

https://doi.org/10.1182/blood.V128.22.648.648

Published: 2016

Journal Articles

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giovanni Palladini, MD PhD, Giampaolo Merlini, MD

Blood (2016) 128 (22): 2140.

https://doi.org/10.1182/blood.V128.22.2140.2140

Published: 2016

NARROW

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Patterns of Relapse after Upfront Therapy in AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only